louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03762980: "Bilateral Training in Stroke Patients"
Official title: Effect of Bilateral Training for Upper Extremities in Chronic Stroke Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Shifa International Hospital
Sponsor class: OTHER
First posted: 2018-12-04
Enrollment: 24
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study was to evaluate the effects of bilateral training for upper extremity in stroke patients and to compare these effects between right and left stroke patients. A Quasi Experimental Study conducted on community stroke survivors. A total of 24 stroke patients were included and divided into Group A (Right hemiplegia) (n=12) and Group B (Left hemiplegia) (n=12). Chronic stroke patients (\>3 months), aged 30-70 years with left or right sided diagnosed stroke patients were included while patients on medication that could affect the cognitive functions or with any other cognitive impairments who are not able to follow commands were excluded. Both groups received the same intervention of with bilateral arm training involving 5 functional tasks to improve the functional activities of daily living in upper extremities. Fugl-Meyer Assessment-Upper Extremity Tool (FMA-UE) and Wolf-Motor Function Test (WMFT) were used to assess as outcome measures.The measurements were obtained at baseline and after 6th week of training. Data was analyzed using SPSS version 21.


Eligibility criteria: Inclusion Criteria:

* left or right-sided chronic stroke patients

Exclusion Criteria:

* Patients with cognitive impairment or unable to follow commands

Primary outcomes:
measure: Wolf Motor Function Test
timeFrame: 6 weeks
measure: Fugl Meyer Assessment-upper Extremity
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06108180: Effectiveness of the Dry Needling Approach in Patients With Tension-Type Headache
Official title: Effectiveness of the Dry Needling Approach in Patients With Tension-Type Headache
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tension-Type Headache
Dry Needling
Lead sponsor: Universidad de Zaragoza
Sponsor class: OTHER
First posted: 2023-10-30
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized Single-Blind Clinical Trial in which the treatment will be administered through 3 sessions of dry needling in the cervical, cranial, and facial musculature in patients with frequent and chronic tension-type headache.


Eligibility criteria: Inclusion Criteria:

* Patients with a diagnosis of tension headache according to IHS

Exclusion Criteria:

* Documented major trauma through medical history in the cervical area and/or recent surgery.
* Pregnancy.
* Generalized pain.
* Inflammatory, hormonal, or neurological disorders.
* Tendon disorders in the upper extremities.
* Severe psychiatric illnesses.
* Inability to complete the form in Spanish.
* Having a pacemaker (due to the use of equipment with magnetic sensors).
* Specific contraindications to invasive or conservative physiotherapy (infection, fever, hypothyroidism, wounds in the puncture area, metal allergies, cancer, systemic diseases, or belonephobia).
* Having received physiotherapy treatment for the condition in the past month.

Primary outcomes:
measure: Active trigger points
timeFrame: 1 month
Secondary outcomes:
measure: cervical ROM
timeFrame: 1 month
Other outcomes:
Locations:
city: Zaragoza
country: Spain
facility: Centro Clínico de Fisioterapia OMT-E
Study officials:
References:
citation: Ferrante T, Manzoni GC, Russo M, Camarda C, Taga A, Veronesi L, Pasquarella C, Sansebastiano G, Torelli P. Prevalence of tension-type headache in adult general population: the PACE study and review of the literature. Neurol Sci. 2013 May;34 Suppl 1:S137-8. doi: 10.1007/s10072-013-1370-4.
citation: Fernandez-de-Las-Penas C, Ge HY, Arendt-Nielsen L, Cuadrado ML, Pareja JA. The local and referred pain from myofascial trigger points in the temporalis muscle contributes to pain profile in chronic tension-type headache. Clin J Pain. 2007 Nov-Dec;23(9):786-92. doi: 10.1097/AJP.0b013e318153496a.
citation: Cerezo-Tellez E, Torres-Lacomba M, Fuentes-Gallardo I, Perez-Munoz M, Mayoral-Del-Moral O, Lluch-Girbes E, Prieto-Valiente L, Falla D. Effectiveness of dry needling for chronic nonspecific neck pain: a randomized, single-blinded, clinical trial. Pain. 2016 Sep;157(9):1905-1917. doi: 10.1097/j.pain.0000000000000591.
citation: Stephens LR, Humphrey JD, Little PB, Barnum DA. Morphological, biochemical, antigenic, and cytochemical relationships among Haemophilus somnus, Haemophilus agni, Haemophilus haemoglobinophilus, Histophilus ovis, and Actinobacillus seminis. J Clin Microbiol. 1983 May;17(5):728-37. doi: 10.1128/jcm.17.5.728-737.1983.
Clinical trial NCT06660680: The Effect of Methylene Blue Infiltrating Injection on Anal Pain After Milligan-Morgan Surgery: a Randomized Controlled Clinical Study
Official title: The Ethics Committee of the Second Hospital of Chinese Medicine
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE3
Conditions: Mixed Hemorrhoids
Keywords: Milligan-Morgan surgery
Lead sponsor: The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Sponsor class: OTHER
First posted: 2024-10-28
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A variety of analgesic strategies are available following mixed hemorrhoids surgery, including pharmacological interventions (7), acupuncture, moxibustion, and electroacupuncture . Medications such as opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used but can be associated with side effects including nausea, vomiting, and gastrointestinal bleeding, with long-term use potentially leading to addiction (8). Complementary therapies require skilled administration and regular treatment sessions.

Methylene blue (MB), a cationic thiazine dye extensively utilized as a biological stain and chemical indicator, has been increasingly recognized for its potential analgesic properties (9). In the present study, methylene blue infiltrating injection (MBI) was administered to treat anal pain resulting from Milligan-Morgan surgery, with the aim of assessing its analgesic efficacy and safety profile.


Eligibility criteria: Inclusion Criteria:①Alignment with the diagnostic criteria for mixed hemorrhoids as outlined in the "American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids" ; ②Provision of informed consent following a thorough comprehension of the study's aims; ③An age bracket of 18 to 75 years; ④Satisfaction of surgical indications.

-

Exclusion Criteria:①Presence of anal fistula, anal fissure, perianal abscess, enteritis, or other intestinal pathologies; ②Patients with known allergies; ③Impaired liver or kidney function; ④Pregnancy or lactation.

-

Primary outcomes:
measure: Pain
timeFrame: pain scores at 6, 24, 48, and 72 hours postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Hefei
country: China
facility: Second hospital affiliated Anhui University of Chinese Medicine
state: Anhui
Study officials:
References:
citation: Anorectal Branch of Chinese Medical Doctor A, Colorectal Surgery Group SSoCMA.
Clinical trial NCT01647880: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
Official title: Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Multiple Sclerosis
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: NeuroCure Clinical Research Center, Charite, Berlin
First posted: 2012-07-24
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In the MOVING study should be examined, whether early therapeutic intervention with fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual evoked potentials (mVEP) after 6 month compared to baseline.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of relapsing-remitting multiple sclerosis (RRMS)
* ability to consent and a written approval
* First acute ON attack to the fit eye within 30 days before screening
* Age 18 - 55 years at screening
* EDSS ≤ 6.0
* No MS Attack except for ON in the last 30 days before screening
* No immunomodulatory therapy for at least three Months (before randomization), or
* strong immunomodulatory therapy with interferon beta or glatiramer acetate for at least 6 months
* visus in the affected eye at least 0.1
* latency of Conventional VEP in the affected eye

  * = 115 ms or difference\> = 15 ms to the opposite side at a Study at least 4 but no more than 6 weeks after Onset of clinical symptoms
* At least 2 T2 lesions typical of MS in a previous MRI

Exclusion Criteria:

* other MS course than RRMS
* any condition which could interfere or prevent the MRI study or other investigations
* known allergy or intolerance, or other contraindication against Gd-DTPA
* Patients with known contraindications to treatment with fingolimod (Gilenya ®) or interferon beta-1b Extavia ®
* Competing diseases which could affect visual functions such as diabetic, retinopathy, glaucoma, retinal detachment

Primary outcomes:
measure: Efficacy parameters
Secondary outcomes:
measure: Efficacy parameters
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité-Universitätsmedizin Berlin
city: Potsdam
country: Germany
facility: Sankt Josefs Krankenhaus Potsdam Neurologie
Study officials:
affiliation: Charite- NeuroCure
name: Olaf Hoffmann, PD Dr. med.
role: STUDY_DIRECTOR
References:
citation: Albert C, Mikolajczak J, Liekfeld A, Piper SK, Scheel M, Zimmermann HG, Nowak C, Dorr J, Bellmann-Strobl J, Chien C, Brandt AU, Paul F, Hoffmann O. Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. BMC Neurol. 2020 Mar 3;20(1):75. doi: 10.1186/s12883-020-01645-z.
Clinical trial NCT00304980: Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status
Official title: Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Plasmodium Falciparum Malaria
Lead sponsor: Institute of Tropical Medicine, Belgium
Sponsor class: OTHER
First posted: 2006-03-21
Enrollment: 3000
Sex: ALL
Minimum age (years): 15
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (SP) versus artemether-lumefantrine (Coartem) when administered to HIV+ and HIV- patients with uncomplicated P. falciparum malaria. Patients will be randomised to one of the 2 treatment and followed up (until day 14 actively) for 45 days.


Eligibility criteria: Inclusion Criteria:

* Man and non-pregnant women aged between 15 and 50.
* P.falciparum mono-infection of at least 1,000 parasites/µl.
* Body temperature ≥ 37.5°C at the moment of enrolment or history of fever in the preceding 48 hrs.
* Consent from patient obtained.

Exclusion Criteria:

* Pregnancy.
* Severe P. falciparum malaria .
* Documented intake of SP or Coartem two weeks or less prior recruitment.
* Other cause(s) of fever.
* Evidence of underlying chronic diseases (cardiac, renal, hepatic, malnutrition).
* History of allergy to study drug, or known allergy to other Sulphur drugs such as co-trimoxazol.

Primary outcomes:
measure: PCR corrected clinical and parasitological outcome at day 45
Secondary outcomes:
measure: Tolerability
measure: Clinical recovery
Other outcomes:
Locations:
city: Ndola
country: Zambia
facility: Tropical Disease Research Center
state: Cupperbelt
Study officials:
affiliation: Institute of Tropical Medicine Antwerp
name: Umberto D'Alessandro, MD,MSc, PHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Van Geertruyden JP, Mulenga M, Mwananyanda L, Chalwe V, Moerman F, Chilengi R, Kasongo W, Van Overmeir C, Dujardin JC, Colebunders R, Kestens L, D'Alessandro U. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis. 2006 Oct 1;194(7):917-25. doi: 10.1086/507310. Epub 2006 Aug 29.
Clinical trial NCT01187680: Efficacy of Sprayable PEG Barrier in Gynecologic Laparoscopy
Official title: Polyethylene Glycol Adhesion Barrier Reduces Adhesions After Gynecologic Laparoscopy; a Prospective Randomized Controlled Pilot Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Postoperative Adhesion
Peritoneal Adhesion, Nos
Keywords: Tissue adhesions
Laparoscopy
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
Collaborators: name: Onze Lieve Vrouwe Gasthuis
First posted: 2010-08-24
Enrollment: 16
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to investigate whether sprayable PEG barrier is effective in reducing adhesions in laparoscopic gynecologic surgery.


Eligibility criteria: Inclusion Criteria:

* \>18 years
* Undergoing gynecologic laparoscopy

Exclusion Criteria:

* Suspected malignancy
* Incomplete adhesiolysis during initial laparoscopy
* Pregnancy
* Lactating
* Stage IV endometriosis

Primary outcomes:
measure: successful adhesion prevention
Secondary outcomes:
measure: LABS adhesion score
measure: Adhesion sites
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Onze Lieve Vrouwe Gasthuis
state: Noord-Holland
Study officials:
References:
Clinical trial NCT00991380: Healthy Eating & Active Living for Diabetes in Primary Care Networks
Official title: Healthy Eating & Active Living for Diabetes in Primary Care Networks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes
Lead sponsor: The Alliance for Canadian Health Outcomes Research in Diabetes
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2009-10-08
Enrollment: 200
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators aim to establish the effectiveness of a prescribed, community-based lifestyle modification program for those with recently diagnosed diabetes. The investigators hypothesize that those who enter a 6 month program will report greater levels of physical activity compared to a group who do not enter the program but who continue to receive usual care.


Eligibility criteria: Inclusion Criteria:

* adult, recent type 2 diabetes diagnosis according to a diabetes patient registry, received a referral to a group-based lifestyle program or some provider-based diabetes related education.

Exclusion Criteria:

* physical limitation, cardiovascular contraindication, participation in any other research study

Primary outcomes:
measure: Physical Activity
timeFrame: 3 months
measure: Physical Activity
timeFrame: 6 months
measure: Physical Activity
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: The Alliance for Canadian Health Outcomes Research in Diabetes
state: Alberta
Study officials:
affiliation: University of Alberta
name: Jeffrey A Johnson, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Alberta
name: Steven T Johnson, PhD
role: STUDY_DIRECTOR
References:
citation: Johnson ST, Bell GJ, McCargar LJ, Welsh RS, Bell RC. Improved cardiovascular health following a progressive walking and dietary intervention for type 2 diabetes. Diabetes Obes Metab. 2009 Sep;11(9):836-43. doi: 10.1111/j.1463-1326.2009.01050.x. Epub 2009 Jul 10.
citation: Mathe N, Johnson ST, Wozniak LA, Majumdar SR, Johnson JA. Alternation as a form of allocation for quality improvement studies in primary healthcare settings: the on-off study design. Trials. 2015 Aug 25;16:375. doi: 10.1186/s13063-015-0904-x.
citation: Johnson ST, Mundt C, Soprovich A, Wozniak L, Plotnikoff RC, Johnson JA. Healthy eating and active living for diabetes in primary care networks (HEALD-PCN): rationale, design, and evaluation of a pragmatic controlled trial for adults with type 2 diabetes. BMC Public Health. 2012 Jun 19;12:455. doi: 10.1186/1471-2458-12-455.
Clinical trial NCT03215680: Climat Impact on Urinary Iodine Concentration
Official title: Assessment of Impact of High Temperature Climate on Urinary Iodine Concentration in Women of Reproductive Age
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Iodine Deficiency
Keywords: Urinary iodine concentration
Lead sponsor: Swiss Federal Institute of Technology
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Tanzania
name: North-West University, South Africa
First posted: 2017-07-12
Enrollment: 363
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy women between 18 and 49 years of age

Brief summary: Urinary iodine concentration (UIC) is the recommended biomarker of iodine status in populations. Yet, the influence of climate on UIC remains unclear. Hot climate may reduce urine volume and consequently increase UIC independent of iodine status. This could lead to an overestimation of population iodine intake, thus masking iodine deficiency in vulnerable groups.

In this longitudinal observational cohort study in women of reproductive age we will collect 24h and spot urine samples in the summer and winter season. The influence of high temperature climates on UIC, measured and estimated urinary iodine excretion will be estimated.


Eligibility criteria: * Female
* Non-pregnant and non-lactating
* General good health, assessed by no reported treatment for chronic disease
* Non-smoking
* No known history of major medical illnesses or thyroid dysfunction as well as gastrointestinal or metabolic disorders and taking no chronic medication
* Residence at the respective study site for 12 months or longer and no plans of moving away during the study year.
* No use of iodine containing dietary supplements during the last 6 months
* No use of X-ray / CT contrast agent or iodine containing medication within the last year
* No use of iodine containing disinfectants during the last 6 months
* Participants should be between 18 and 49 years at date of enrollment

Primary outcomes:
measure: Urinary iodine concentration
timeFrame: 6 months
Secondary outcomes:
measure: Urinary iodine excretion
timeFrame: 6 months
Other outcomes:
measure: Urinary iodine concentration
timeFrame: 6 months
measure: Urinary iodine excretion
timeFrame: 6 months
Locations:
city: Potchefstroom
country: South Africa
facility: Centre of Excellence for Nutrition, Faculty of Health Science, North West University
city: Dar es Salaam
country: Tanzania
facility: Ministry of Health, Community Development Gender, Elderly and Children
Study officials:
affiliation: ETH Zurich
name: Michael B Zimmermann, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Arns-Glaser L, Zandberg L, Assey VD, Baumgartner J, Abdallah F, Galetti V, Dary O, Zimmermann MB, Andersson M. Seasonal effects on urinary iodine concentrations in women of reproductive age: An observational study in Tanzania and South Africa. Am J Clin Nutr. 2022 Jan 11;115(1):298-309. doi: 10.1093/ajcn/nqab327.
Clinical trial NCT02535780: Transcranial Treatments in Eating Disorders
Official title: Novel Transcranial Treatments to Modulate Taste Reward and Body Perception Pathways in Eating Disorders
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Anorexia Nervosa
Bulimia Nervosa
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2015-08-31
Enrollment: 1
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary aim of this study is to study how Repetitive Transcranial Magnetic Stimulation (rTMS) tailored to specific anorexia nervosa (AN) or bulimia nervosa (BN) brain activation alterations will promote recovery and to study how inhibitory tDCS (Transcranial Direct Current Stimulation) will reduce symptoms of body image distortion in a second sample of AN and BN groups.


Eligibility criteria: Inclusion Criteria:

* Anorexia Nervosa subjects:
* Meets DSM-5 criteria for anorexia nervosa (AN) either binge-eating/purging type or restricting-type:
* Intense fear of gaining weight or becoming fat, even though underweight.
* The ability to undergo an MRI, fMRI or other similar procedure requiring spending time in an enclosed space
* Bulimia Nervosa subjects:
* Meet DSM-5 criteria for bulimia nervosa (BN):
* Self-induced vomiting; misuse of laxatives, diuretics, enemas, medication, fasting, excessive exercise.

Exclusion Criteria:

* Electrolyte, blood count or kidney or liver function abnormalities.
* No symptoms of alcohol or other substance abuse or dependence in the past 3 months,
* No previous or current organic brain syndromes, dementia, psychotic disorders, somatization disorders, or conversion disorder, head trauma, indication of mental retardation or pervasive developmental disorder.
* No antipsychotics, tricyclic antidepressants or Wellbutrin or other medication that may lower the seizure threshold.
* Claustrophobia.

Primary outcomes:
measure: taste reward brain function activation confirmed by Functional magnetic resonance imaging (fMRI)
timeFrame: 3 years
Secondary outcomes:
measure: Change in self-reported measures related to eating disorder thoughts and behaviors
timeFrame: 3 years
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Denver and Health Science Center
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Guido K. Frank, MD
role: PRINCIPAL_INVESTIGATOR
References: